AdvaMed® Statement on President’s Reciprocal Tariff Pause
WASHINGTON – Today AdvaMed, the MedTech Association®, released the following statement from President and CEO Scott Whitaker:
“We are encouraged by the President’s announcement of a 90-day pause on reciprocal tariffs. This is an important decision that restores some short-term certainty to global markets, including the American medtech industry, which is number one globally.
“Moving forward, we will spend the next 90 days working with the President and his senior team to ensure the unique role of the medtech industry is protected, with the hope that the ultimate outcome is ‘zero for zero’ tariffs on medtech with all key trading partners.”
Related Reading
News / Diagnostics / Digital Health / Government & Legislative Affairs / Regulatory Affairs
AdvaMed Statement on the Nomination of Dr. Heidi Overton as FDA Commissioner
August 19, 2026
WASHINGTON—Scott Whitaker, president and CEO of AdvaMed, the medtech association, made the following comment on President Trump’s nomination of Dr. Heidi Overton to serve as FDA commissioner.
News / Government & Legislative Affairs / Regulatory Affairs / Small Business
AdvaMed Names Juan Carlos “JC” Scott Chief Strategy Officer and Executive Director of AdvaMed Accel
August 12, 2026
WASHINGTON, D.C. – AdvaMed today announced that Juan Carlos “JC” Scott has been appointed Chief Strategy Officer and Executive Director of AdvaMed Accel, a newly created leadership position focused on accelerating engagement with emerging medical technology companies and strengthening AdvaMed’s role at the center of the innovation ecosystem.
Resource / Government & Legislative Affairs
Scott Whitaker Op-Ed: Medtech: A great value in American health care
August 7, 2026
Medicare breakthrough medical technologies face delays between FDA authorization and coverage decisions, slowing patient access to innovation.
Event / AdvaMed Advancements / Business Development / Government & Legislative Affairs / Regulatory Affairs / Small Business
AdvaMed® Medtech Showcase
September 16, 2026
5:00 PM – 7:00 PM
Experience the future of health care at the 2026 Medtech Showcase and Reception on Capitol Hill. Join AdvaMed® on September 16 for an interactive event featuring more than 25 medtech companies demonstrating breakthrough technologies that are transforming patient care. See innovative medical devices firsthand, connect with industry leaders and policymakers, and discover how medtech innovation is improving and saving lives.
News / Government & Legislative Affairs / Regulatory Affairs
AdvaMed Strongly Supports Draft MDUFA VI Agreement at FDA Public Meeting
August 5, 2026
WASHINGTON, D.C.—AdvaMed, the Medtech Association, today expressed strong support for the draft Medical Device User Fee Amendments (MDUFA) VI agreement at an FDA public hearing.
Resource / Coverage & Payment / Government & Legislative Affairs / Health Access
Gateways to Health: How Medtech Is Improving Care While Lowering Healthcare Costs
July 31, 2026
Read Gateways to Health, a special publication exploring how medical technology improves patient care, expands access, and lowers healthcare costs.
Resource / AdvaMed Advancements / Emerging Policy Response Resources / Global & Trade / Tariffs
AdvaMed® Advancements: Q2 2026 Report
July 14, 2026
Explore AdvaMed’s Q2 2026 Report to see how advocacy, member engagement, and policy progress are advancing innovation and strengthening the medtech industry.
News / Government & Legislative Affairs / Regulatory Affairs
AdvaMed Welcomes Key Developments in MDUFA VI Process
July 8, 2026
WASHINGTON, D.C.—AdvaMed, the Medtech Association, today welcomed next steps in the Medical Device User Fee Amendments reauthorization process following clearance by the White House Office of Management and Budget of the draft MDUFA VI agreement.